Reports Q2 revenue $93,000 vs. $96,000 last year. David Jenkins, CEO, commented: “During the second quarter of 2024, we focused on acquiring additional talent for the US to support our new sales strategy under the new Chief Commercial Officer, Marie-Claude Jacques. During this time, we also recognized initial revenue for LockeT and continued marketing VIVO in new US territories.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTAK:
- Catheter Precision announces publication of LockeT data
- Catheter Precision Converts Series A Preferred Stock
- Catheter Precision completes enrollment of 75 patients in LockeT-II study
- Catheter Precision completes patient follow-up for VIVO European Registry
- Catheter Precision announces effectiveness of 1-for-10 reverse stock split